scorecardresearch
Wednesday, April 24, 2024
TopicCovishield

Topic: Covishield

AstraZeneca vaccine safe, effective in kids, finds Lancet study. WHO still says for adults only

The vaccine, marketed as Covishield in India, induced antibody concentrations in children similar to those associated with high efficacy in adults, says study by UK researchers.

Didn’t suit global narrative that Indian firm could deliver quality, says SII’s Poonawalla

CEO of world’s largest vaccine maker says India is better equipped to deal with pandemics now, adds a global treaty is important to allow resource-sharing across borders.

‘No demand’: In Covishield’s home Pune, 1.41 lakh doses at private centres about to expire

Private hospitals in Pune municipal limits are staring at major vaccine wastage, blame free government drives and strict rules for booster eligibility and second dose gap.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

Covishield, Covaxin prices may drop to Rs 275/dose after getting regular market approval

Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.

Not allowing Covishield, Covaxin retail sale meaningless. Indians need vaccines and boosters

ThePrint view on the most important issues, instantly.

Covishield shows increased antibody response to Omicron after 3rd dose: AstraZeneca

Preliminary data released by AstraZeneca shows Vaxzevaria vaccine, administered in India as Covishield, increased immune response to Beta, Delta, Alpha, Gamma variants after third dose.

No trial data on 3 shots of Covaxin, as precaution dose begins from next Monday

Trial on third Covaxin shot ongoing, results to be out soon, says Bharat Biotech. ICMR officials say 9-month interval based on studies that show antibodies last 6-13 months.

Govt says no Covaxin supply issue: 5 cr doses with states, 10 cr more coming in next 2 months

Only Covaxin will be used for vaccinating an estimated 7.4 crore 15-18-year-olds, so finding a slot for the first shot of the indigenous vaccine could get more difficult.

On Camera

Climate change doesn’t just affect poor people, farmers. Cities and banks aren’t safe either

In India, only 17% of public sector banks and 25% of private sector banks claimed to have an internal strategy for integrating climate risks into their risk management framework.

Economists vs statisticians — the battle being fought over the soul of India’s GDP data

Economists say there are weaknesses in India’s GDP data. But statisticians claim the accusations are based on flawed understanding, saying while GDP has problems, the economists are looking in the wrong places.

India, Oman hold 5th annual high-level meeting to boost maritime security

Both the governments expressed their commitment to strengthening their maritime cooperation to strengthen the maritime safety and security framework in the region.

These 6 states are key for Modi’s ‘400 paar’ target. They’re also where Opposition can stop him

While this contest looks so predictable in large swathes of our political landscape, it is also more keenly contested than 2019 in some states.